I am a neuroscientist and executive, trained by world-leading experts from Johns Hopkins University School of Medicine, Howard Hughes Medical Institute, UC Berkeley, Halifax University and BGU.I identified key mechanisms leading to neurodegeneration and neuronal rewiring, developed novel biomarkers and discovered innovative therapies (TBI, stroke, epilepsy, SCA3, AD, ADHD, MDD), including the first treatment for preventing the development of epilepsy (epileptogenesis). Hold extensive financial and budgetary experience; planned and managed of multi-million-dollar projects and budgets.Currently serving as the Executive Director of Research & Strategy at Neurocentria, a late-phase biotech company, leading the company’s programs in ADHD (phase 3), MDD (phase 3) and Alzheimer’s disease (phase 2b), as well as translational research and regulatory affairs, with a track record of three approved INDs.Known for extensive scientific and management expertise with polished people skills. Recognized for creating team-oriented environments with a high level of dedication, projects management and time-line oriented outcome. Out-of-the-box, analytic thinker with outstanding oral and written communication skills. Promoted to positions of increasing authority and responsibility due to strong leadership skills, research capabilities and overall performance.My true passion is to bring life-changing therapies for those with great unmet medical need and their families using revolutionary science and pioneering programs. This drives me to excellence with unlimited internal motivation.You are invited to contact me via a direct message or at guy.bar@gmail.com.